Supplementary Material and Methods
All the Fmoc-protected amino acids were purchased from AnaSpec (Fremont, CA). TentaGel resin was purchased from Rapp Polymere GmbH (German). All other reagents were purchased from Sigma-Aldrich or Alfa Aesar, unless otherwise specified. All of the chemical reagents and solvents from commercial sources were used without further purification. 5 mL and 10 mL disposable reaction columns (Intavis AG) were used as reaction vessels for solid phase synthesis. Syntheses of peptiods under microwave conditions were performed in a 1500 W microwave oven (GE model JE 1860BH04) with 10% power. HPLC was carried out on Waters systems equipped with Waters 1525 binary HPLC pumps and a 2487 dual λ absorbance detector, or a 2998 photodiode array detector. The mobile phase comprised of buffer A (H2O containing 20% CH 3 CN and 0.1% trifluoroacetic acid (TFA)) and buffer B (CH 3 CN containing 0.1% TFA). Analytical HPLC was conducted using a Vydac C-18 column (5 µm, 250 x 4.6 mm, Alltech, Deerfield, IL) at a flow rate of 1.0 mL/min with UV detection at 220 nm. MS and MS/MS (MALDI-TOF) were performed on a 4800 Proteomics Analyzer (Applied Biosystems) with α-cyano-4-hydroxycinnamic acid (CHCA) as a matrix. All steps involving water utilized distilled water filtered through a Barnstead Nanopure filtration system (Thermo Scientific)
Library Synthesis
The peptoid library was linked to Tentagel HL-NH 2 beads (75 µM diameter, 0.45 mmol/g) by a fixed sequence of amino acid and peptoid residues as shown in the main text. Resin (2.0 g, approximately 10 7 beads) was swelled in DMF for 2 hours prior to use. Amino acids were coupled with diisopropylcarbodiimide (DIC) and ethyl-2-cyano-2-(hydroxyimino) acetate (Oxyma) in DMF without base added to prevent possible racemization (Amino acid: DIC: Oxyma: bead capacity = 4:4:4:1). Methionine was the first amino acid loaded onto the resin. After methionine coupling, Fmoc was removed by 20% piperidine and washed thoroughly in DMF. The rest of the linker was synthesized by standard peptoid sub-monomer synthesis as previously described 1 .
A 95:5 mixture of orthogonally protected glutamic acid esters (Fmoc-Glu(OAll)-OH : FmocGlu(OtBu)-OH 95:5, 4 equiv) was used at the last position of the linker region. Fmoc was removed by 20% piperidine and washed thoroughly in DMF. Split and pool synthesis was used to construct the variable region with a theoretical diversity of 50,625 compounds. This was accomplished by incorporating the 15 amines listed in the main text via microwave-assisted sub-monomer peptoid synthesis at four variable positions. Following peptoid synthesis, a fixed region with 0-2 N-methoxyethylamine peptoid units was added to vary the length of different libraries. Allyl esters were deprotected by Pd(0)(PPh 3 ) 4 (2 equiv) in 37:2:1 ACN: Morpholine: AcOH M under argon for 2 h at room temperature. All beads were then washed with 0.5% DIEA and 0.5% sodium diethyldithiocarbamate in DMF for three times, 5 min each. Cyclization was carried out with PyBOP (4 equiv, 1M) and DIEA (10 equiv, 2.5M) in DMF for 2 hours, and repeated once. Following cyclization, the beads were treated with a mixture of 94% TFA, 2% triisopropylsilane, 2% water, and 2% thioanisole mixture for 2 h to remove side chain protecting groups. After draining the TFA mixture, the beads were washed thoroughly with DCM, then with DMF. For hit resynthesis, each compound was synthesized following the procedure described above except for the variable region, which was synthesized according to the hit sequence. All re-synthesized hit compounds were purified by HPLC and dried by lyophilization.
On-bead Screening
Approximately 500,000 beads, 10 equivalents of theoretical diversity, from each library were combined to form a pool of 3,000,000 beads. Hit compounds were isolated by magnetic screening method as previously described 2 . Specifically, all beads were first thoroughly washed with DMF, then gradually washed with 7:1 DMF:water, 2:1 DMF:water, 1:1 DMF:water, 1:2 DMF:water, 1:7 DMF:water solutions for three times each. To completely remove DMF, all beads were then washed several times with water and then with TBST buffer (50 mM Tris, pH 7.4, 150 mM, NaCl, 0.1% Tween-20) and equilibrated with TBST overnight. Before screening all beads were incubated with Starting Block TBS blocking buffer (Pierce) at room temperature for 4 h. The blocking buffer was filtered out and the beads were incubated with 1:25 (2 ml in 50 ml buffer) streptavidin-coupled Dynabeads M-280 (Invitrogen) in blocking buffer for 2 hours at room temperature. After incubation, hit beads were isolated with a strong magnet. These beads were collected and stripped of bound protein by incubating in 50% acetonitrile/water (3 x 5 mL) for 30 min followed by incubation in acetonitrile for 60 min. Each bead was then isolated into a single well of a 96-well filter plate (Millipore) and washed with water.
Fluorescent Polarization Assay
For single-bead labelling with fluorescein azide, 130 µl of a 1:1 mixture of t-BuOH and water was first added to each well. A fluorescein azide (structure shown above) methanol solution (0.3 mM) was dispensed to each well, 10 µl per well. 10 µl of freshly prepared water solution of CuSO 4 (0.3 mM) and ascorbic acid (0.6 mM) was then dispensed to each well, and the whole plate was sealed and left on shaker for 24 hours. Final concentrations were: fluorescein azide (20 µM), CuSO 4 (20 µM), ascorbic acid (40 µM). The beads were then thoroughly washed with water and then CH 3 CN. Compound was cleaved from the bead by incubating each bead in 20 µL of a 50 mg/ml solution of cyanogen bromide (CNBr) dissolved in AcOH:CH 3 CN:water (5:4:1) overnight at room temperature. The next day, the CNBr solution was evaporated by vacuum centrifugation. After drying under vacuum, the cleaved compounds were dissolved in 60% acetonitrile/water, the final concentration of all the compounds were normalized to 100 nM by UV absorption at 495nm (ε 495 = 78,000 M ). Serial dilution of the streptavidin (homo-tetramer) in PBS buffer was dispensed in 384-well plate, 10 µl each, and then the dissolved compounds in PBS were added in each well. The whole plate was then mounted on EnVision plate reader (Perkin-Elmer), and FP data was taken as direct read outs of each well in mP using 450 excitation and 515 nm emission filters. Fitting of the saturation curves to obtain K D values was accomplished using Prism (GraphPad Software, Inc.) with a one-site specific saturation binding model. For re-synthesized compounds, after purification, each compound was dissolved in PBS buffer to obtain a 100 nM solution. Serial dilutions of streptavidin were prepared in a 96-well plate, 50 µl per well. 50 µl of compound solution was added to each well and K D values were obtained as described above.
All 450 hit identified from screening were measured using this method. The raw K D values are listed in Table S3 . Sequences were obtained by tandem mass spectroscopy.
To determine if the identified compounds bind to streptavidin at the same binding site of biotin, we performed a biotin competition assay. Re-syntehsized KYG-1171 and KYG-1181 were measured by FP at the presence of 0 µM, 320 µM and 1 mM biotin respectively. K D values were obtained from fitting FP data as described above. As shown in Figure S3 , no significant change was observed, suggesting that KYG-1171 and KYG-1181 do not bind to the biotin-binding site.
Hit characterization
For hit sequence identification, all solution was first evaporated by vacuum centrifugation and the dry compound in each well was dissolved in 20 µL of a 75:25 mixture of water:CH 3 CN containing 0.1% TFA. 0.6 µL from each well was co-spotted with a 10 mg/mL solution of CHCA dissolved in 50% acetonitrile in water containing 0.1% TFA. The spot was dried, and the mass spectra and tandem mass spectra of these compounds were collected using a 4800 Plus MALDI TOF/TOF Analyzer (Applied Biosystems). For quality control purpose and to determine if sequence from different libraries could be differentiated, 20 beads S5 were isolated manually from each library. All 120 beads are combined sequenced as a pool. The results are listed in Table S2 . Figure S1 . Figure S1 . Optimization of cyclization efficiency of peptoids with various ring sizes. Besides the desired cyclic product, dimer and uncyclized linear peptoids are identified as major by-products. Table S1 . Table S1 . Optimization of macrocyclization condition. Reaction as shown in Figure S1 .
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Percentage of linear, dimer and cyclized products are determined by HPLC peak areas. Figure 1 . The source of each sequence is listed in the last column. 
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